Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccinationEspen B. Ellingsen, Gustav Gaudernack, Donjetë Simnica et al.|Journal of Translational Medicine|2022Cited by 21
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in miceAman Mebrahtu, Sara M. Mangsbo|Nature Communications|2024Cited by 10
382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanomaEspen B. Ellingsen, Gustav Gaudernack, Iliana Kerzeli et al.|Regular and Young Investigator Award Abstracts|2021Cited by 0